| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K24690302 | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.025 | 0.4 |
| mRNA | BRD-K09587429 | CTRPv2 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | -0.026 | 0.4 |
| mRNA | GDC-0941 | GDSC1000 | pan-cancer | AAC | -0.025 | 0.4 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.04 | 0.4 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | 0.029 | 0.5 |
| mRNA | CAY10618 | CTRPv2 | pan-cancer | AAC | -0.026 | 0.5 |
| mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | -0.027 | 0.5 |